​Amazon Financial Analysis

This Amazon financial analysis project combines income statement, balance sheet, and cash flow forecasts with advanced valuation models. The workbook includes ratio analysis, DuPont decomposition, WACC and beta calculations, and a full discounted cash flow (DCF) model to estimate intrinsic value. Scenario forecasting and macroeconomic assumptions are layered in to stress test results, while historical stock price data supports validation. Overall, the project demonstrates a complete, professional-grade equity valuation framework applied to Amazon.
Eli Lilly Equity Research
BUY

Eli Lilly (LLY)

Equity Research Report | Dec 21, 2023

Current Price $579.00
Target Price $632.00
Expected Return +9.15%
Market Cap $550.42B
Shares Outstanding 950.63M
52 Week High $629.97
52 Week Low $309.20
Earnings per Share $6.93
Price / Earnings Ratio 88.14x
Forward Dividend (Yield) $5.20 (0.90%)

Equity Research Report: Eli Lilly Discounted Cash Flow Model

My valuation analysis, using both Discounted Cash Flow (DCF) with Free Cash Flow to the Firm (FCFF) and Equity (FCFE) and relative valuation methods, suggests Eli Lilly's current stock price of $579 aligns closely with our target range of $601 to $678 and a target price of $632, making this a buy. Key factors impacting this valuation include:
  1. Inflation Reduction Act's Impact: Upcoming drug price negotiations by the U.S. Department of Health and Human Services, affecting Eli Lilly's pricing dynamics by 2026 (Medicare Drug Price Negotiation | CMS, n.d.).
  2. Development of a Weight Loss Drug: The promising trial results of Eli Lilly's patent-pending weight loss drug significantly influence its market value.
  3. Advancements in Cancer Treatment: Eli Lilly's progress in Retevmo’s (RETs) cancer therapy contributes to its positive valuation.
Eli Lilly reached its 52-week high in November following these developments, indicating strong market confidence in its prospects.
​

H1-B Visa Trends and Job Market Outlook for Commodity Analysts in 2025

The landscape for commodity analysts in the United States continues to evolve, shaped by both domestic economic factors and international workforce trends. This report examines current H-1B visa patterns and employment prospects for commodity analysts, providing insights for industry professionals, employers, and international job seekers in this specialized field.

​The H1-B cases in this dataset (176 total) are concentrated in finance and quantitative commodity analyst roles, with a median salary of $100K and a range between $80K and $193K. New York City and major financial firms like JPMorgan, Nomura, and Goldman Sachs lead sponsorship, highlighting the strong demand for international talent in financial analysis, risk, and quantitative positions.

​COVID-19 Insights with Tableau: Vaccine Coverage, Death Rates, and Infection Trends

The data highlights a strong relationship between vaccine coverage, recovery, and death rates across countries. Most nations cluster at lower vaccine coverage levels, with only a few achieving higher ratios that noticeably reduce death rates. The “Doses to Recovery” and “Vaccine Coverage to Death Ratio” plots suggest that while vaccine distribution has improved outcomes in many regions, disparities remain—particularly in countries with large populations where coverage lags behind infections and recoveries.
At the country level, India, the U.S., and Brazil show the highest death and infection rates, reflecting both scale and early struggles with containment. European countries like Spain, Italy, and the U.K. also rank high in mortality, while nations with stronger vaccine campaigns tend to show lower average death rates relative to cases. Overall, the dashboard underscores how uneven vaccine access and coverage directly shaped the trajectory of infections, recoveries, and mortality worldwide.